Statin Referrals & Prescriptions: 6x Increase
- A new study reveals that automated referrals to pharmacy services dramatically improve the likelihood of patients receiving the correct dose of statins, medications used to lower "bad" cholesterol.Researchers...
- With over 90 million Americans using statins, addressing suboptimal prescribing trends is crucial.
- Typically,physicians evaluate a patient's cardiovascular risk and determine the need and dosage for statins.
A groundbreaking study reveals automated pharmacy referrals drastically boost the prescription of appropriate statin dosages. Researchers discovered a remarkable sixfold increase in proper statin prescriptions via this innovative approach,directly addressing the under-prescription of statins for cholesterol management. This is crucial, given nearly 90 million Americans rely on statins. By seamlessly connecting patients with pharmacists, this automated system ensures patients receive the optimal dosage of this vital primary_keyword medication. This innovative approach could revolutionize cholesterol treatment.The study highlights the potential of technology to enhance patient care adn cardiovascular health. Read on to investigate the use of secondary_keyword referrals within a trial. News Directory 3 highlights the key takeaways from this impactful research. Discover what’s next as the study explores long-term health outcomes and future cost-effectiveness.
Automated Pharmacy Referrals Boost Appropriate Statin Prescriptions
Updated June 25, 2025
A new study reveals that automated referrals to pharmacy services dramatically improve the likelihood of patients receiving the correct dose of statins, medications used to lower “bad” cholesterol.Researchers at the University of Pennsylvania’s Perelman school of Medicine found that this approach increased appropriate statin prescriptions sixfold compared to traditional methods.
With over 90 million Americans using statins, addressing suboptimal prescribing trends is crucial. While statins effectively reduce cholesterol adn cardiovascular disease risk, many patients who could benefit are either not prescribed statins or receive doses that are too low.
Typically,physicians evaluate a patient’s cardiovascular risk and determine the need and dosage for statins. However, time constraints often hinder thorough preventive care. An automated system identifying patients needing statins or higher doses, and then referring them to pharmacists, offers a promising solution to ensure proper cholesterol management.
the research team, as part of the Penn Medicine Atherosclerotic Cardiovascular Disease Risk Reduction Initiative, conducted a trial across ten primary care practices within the Penn Medicine lancaster General Health System. They assessed the impact of automatically referring eligible patients-those not already on statins-to a centralized pharmacy service. Pharmacists then contacted these patients to discuss individual risks and the benefits of statin therapy, initiating treatment when appropriate. The primary goal was to measure the proportion of patients prescribed statins, with a secondary focus on guideline-recommended dosages.
The trial involved 1,950 eligible patients, with 975 in the intervention group receiving automated referrals. The initial assessment showed that 86.4% of eligible patients were not on statins, while the remainder received inadequate doses. The intervention group saw a important increase, with 31.6% receiving a statin prescription compared to only 15.2% in the usual care group. Furthermore, 24.8% in the intervention group were prescribed guideline-recommended doses, versus 7.7% in the usual care group.
According to Fanaroff, “The findings suggest that automated referrals to centralized pharmacy services for lipid management are a game-changing strategy, drastically improving the odds of prescribing appropriate dose statins.”
What’s next
Further research will explore the long-term impact of automated pharmacy referrals on patient health outcomes and cost-effectiveness within broader healthcare systems. The study was funded by a National Institutes of Health Clinical and Translational Science Award Grant (UL1TR001878).